These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Harris MG; Coleman SG; Faulds D; Chrisp P Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188 [TBL] [Abstract][Full Text] [Related]
7. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies. Hucher M; de Gery A; Bertagna C Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510 [No Abstract] [Full Text] [Related]
8. Nilutamide: an antiandrogen for the treatment of prostate cancer. Dole EJ; Holdsworth MT Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470 [TBL] [Abstract][Full Text] [Related]
9. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer. Eastham JA; Sartor O J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206 [No Abstract] [Full Text] [Related]
10. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. Kassouf W; Tanguay S; Aprikian AG J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822 [TBL] [Abstract][Full Text] [Related]
12. [Complete androgen blockage in the treatment of metastatic prostate cancer]. Matzkin H; Braf Z Harefuah; 1994 Mar; 126(5):260-3. PubMed ID: 8188104 [No Abstract] [Full Text] [Related]
13. Design of antiandrogens and their mechanisms of action: a case study (anandron). Raynaud JP; Fiet J; Le Goff JM; Martin PM; Moguilewsky M; Ojasoo T Horm Res; 1987; 28(2-4):230-41. PubMed ID: 3331376 [TBL] [Abstract][Full Text] [Related]
14. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group. Janknegt RA Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and metabolism of nilutamide. Creaven PJ; Pendyala L; Tremblay D Urology; 1991; 37(2 Suppl):13-9. PubMed ID: 1992598 [TBL] [Abstract][Full Text] [Related]
16. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793 [TBL] [Abstract][Full Text] [Related]
17. The place and the results of monotherapy. Bonnet P Acta Urol Belg; 1998 May; 66(2):11-5. PubMed ID: 9633120 [No Abstract] [Full Text] [Related]
19. What is an antiandrogen and what is the physiological and pharmacological rationale for combined "castration" + "antiandrogen" therapy. Moguilewsky M; Cotard M; Proulx L; Tournemine C; Raynaud JP Prog Clin Biol Res; 1987; 243A():315-40. PubMed ID: 3116549 [No Abstract] [Full Text] [Related]
20. Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect? Decensi A; Torrisi R; Fontana V Br J Cancer; 1994 Mar; 69(3):617-9. PubMed ID: 8123500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]